Diane Weiser | VP, Corporate Communications, and IR |
Robert Blum | President and CEO |
Bradley Morgan | SVP, Research and Non-Clinical Development |
Fady Malik | EVP, Research and Development |
Peter Roddy | SVP and CAO |
Ching Jaw | SVP and CFO |
Jeffrey Hung | Morgan Stanley |
Joseph Pantginis | H.C. Wainwright |
Jason Butler | JMP Securities |
Pete Stavropoulos | Cantor Fitzgerald |
Gill Bloom | Needham & Company |
Good afternoon and welcome, ladies and gentlemen, to the Cytokinetics' Third Quarter 2018 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the call for questions and answers after the presentation. I will now turn the call over to Diane Weiser, Cytokinetics Vice President of Corporate Communications and Investor Relations. Please go ahead.